Search results for Certolizumab

Certolizumab Biosimilar – Anti-TNF-Alpha mAb – Research Grade, ProteoGenix, PX-TA1024

Description of Certolizumab Biosimilar - Anti-TNF-Alpha mAb - Research Grade Certolizumab Biosimilar: A Promising Anti-TNF-Alpha Monoclonal Antibody for Therapeutic Targeting Certolizumab Biosimilar is a novel monoclonal antibody (mAb) that has gained significant attention in the field of immunotherapy due to its potential as a therapeutic agent for various inflammatory and autoimmune diseases. This biosimilar is a highly specific and potent inhibitor of tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine involved in the pathogenesis of several chronic inflammatory disorders. In this article, we will delve into the structure, activity, and potential applications of Certolizumab Biosimilar as an anti-TNF-α mAb in research settings. Structure of Certolizumab Biosimilar Certolizumab Biosimilar is a recombinant, fully humanized IgG1 monoclonal antibody that is produced by a mammalian cell expression system. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Certolizumab Biosimilar specifically binds to TNF-α, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). One unique feature of Certolizumab Biosimilar is the absence of the Fc region, which is responsible for effector functions in other mAbs. This is achieved by replacing the Fc region with a 40 kDa polyethylene glycol (PEG) molecule, resulting in a smaller molecular weight of 90 kDa compared to other anti-TNF-α mAbs. This modification not only enhances the half-life and stability of the antibody, but also reduces the risk of immunogenicity and potential adverse effects. Activity of Certolizumab Biosimilar The main mechanism of action of Certolizumab Biosimilar is the neutralization of TNF-α, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ankylosing spondylitis. TNF-α is known to induce inflammation, tissue damage, and bone erosion by activating immune cells and promoting the production of other inflammatory cytokines. By binding to TNF-α, Certolizumab Biosimilar prevents its interaction with its receptors and inhibits downstream signaling pathways, thereby reducing inflammation and disease progression. Moreover, the PEGylation of Certolizumab Biosimilar also contributes to its activity by prolonging its half-life and reducing its clearance from the body. This allows for a longer duration of action and potentially lower dosing frequency compared to other anti-TNF-α mAbs, making it a more convenient and cost-effective option for patients. Applications of Certolizumab Biosimilar Certolizumab Biosimilar has been extensively studied and has shown promising results in clinical trials for various inflammatory and autoimmune diseases. In particular, it has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease in several countries, including Europe and Japan. It is also being investigated for its potential in other indications such as ulcerative colitis, axial spondyloarthritis, and non-infectious uveitis. In research settings, Certolizumab Biosimilar is widely used as a tool to study the role of TNF-α in disease pathogenesis and to evaluate the efficacy of anti-TNF-α therapies. Its unique structure and mechanism of action provide a valuable platform for developing new and improved anti-TNF-α mAbs with enhanced properties and reduced side effects. Conclusion In summary, Certolizumab Biosimilar is a promising anti-TNF-α monoclonal antibody with a unique

Certolizumab, Abbexa, abx831580

Certolizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNF(DIF, TNF-alpha, TNFA, TNFSF2, cachexin, cachectin, TNFα), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Certolizumab Antibody, Abbexa, abx376608

Certolizumab Antibody is a rabbit polyclonal antibody for the detection of Certolizumab.

Certolizumab ELISA Kit, Abbexa, abx395017

Certolizumab ELISA Kit is a quantitative ELISA kit for detection of Certolizumab.Certolizumab pegol is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It does not contain an FC region and therefore does not cause antibody-dependent cell-mediated or complement-dependent cytotoxicity as described for infliximab, etanercept, and adalimumab. Another difference is that certolizumab pegol preferentially penetrates inflamed tissue compared to noninflamed tissue, and does so to a greater extent than adalimumab or infliximab. It is directed against soluble and membrane-associated human TNF-α and was approved for the treatment of Crohn’s disease that does not respond to conventional therapy in 2008 and for RA in 2009.

Certolizumab ELISA Kit, ProteoGenix, KPTX128

Description of Certolizumab ELISA Kit The Structure of Certolizumab ELISA Kit Certolizumab ELISA Kit is a highly sensitive and specific immunoassay designed for the quantitative measurement of certolizumab in various biological samples. The kit is based on the principle of enzyme-linked immunosorbent assay (ELISA), which utilizes the binding interaction between an antibody and its corresponding antigen. The Certolizumab ELISA Kit contains all the necessary components for the detection of certolizumab, including precoated microplate, standards, controls, and detection reagents. The precoated microplate is coated with a monoclonal antibody that specifically recognizes certolizumab. This antibody is immobilized on the surface of the microplate, allowing for the capture of certolizumab present in the sample. The Activity of Certolizumab ELISA Kit The activity of Certolizumab ELISA Kit is based on the principle of competitive ELISA. In this assay, the certolizumab present in the sample competes with a certolizumab-horseradish peroxidase (HRP) conjugate for binding to the immobilized certolizumab antibody on the microplate. The amount of certolizumab present in the sample is inversely proportional to the signal generated by the HRP conjugate. This signal can be measured spectrophotometrically and is directly proportional to the amount of certolizumab present in the sample. The Application of Certolizumab ELISA Kit Certolizumab is a monoclonal antibody that specifically targets and inhibits tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Certolizumab is used as a therapeutic agent for the treatment of these diseases. The Certolizumab ELISA Kit is a valuable tool for monitoring the levels of certolizumab in patients undergoing treatment with this therapeutic agent. It can be used to measure the concentration of certolizumab in serum, plasma, and other biological samples, providing important information on the drug’s pharmacokinetics and efficacy. In addition, the Certolizumab ELISA Kit can also be used in research studies to investigate the pharmacodynamics of certolizumab and its mechanism of action. It can be used to determine the levels of certolizumab in animal models and in vitro cell culture systems, providing valuable insights into the drug’s activity and potential side effects. Furthermore, the Certolizumab ELISA Kit can be used in clinical trials to evaluate the efficacy of certolizumab in different patient populations. It can be used to compare the levels of certolizumab in responders and non-responders, as well as to monitor the drug’s long-term effects on patients. In conclusion, Certolizumab ELISA Kit is a highly sensitive and specific assay that provides accurate and reliable measurement of certolizumab levels in various biological samples. Its application in clinical and research settings makes it an essential tool for the evaluation and monitoring of certolizumab as a therapeutic agent.

Anti-Certolizumab Polyclonal Antibody, AntibodySystem, PAB94405

Research Grade Certolizumab (HF879016), abinScience, HF879016

Certolizumab Biosimilar - Research Grade, ichor.bio, ICH5309

Detects human TNFA